Company ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-10.69%		+43.42%	+22.41%

Apr. 10	ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	CI
Mar. 26	ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	CI

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.

Number of employees: 18

USD in Million	2022	Weight	2023	Weight	Delta
New Drugs and Medical Devices 100.0 %	1	100.0 %	0	100.0 %	-84.28%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	0	100.0 %	-84.28%

Managers	Title	Age	Since
Uttam Yashwant Patil CEO	Chief Executive Officer	-	23-06-22
Leeds Chow DFI	Director of Finance/CFO	35	21-02-28
Eugene Jiang CHM	Chairman	38	15-06-30
Tsung-Shann Jiang CTO	Chief Tech/Sci/R&D Officer	70	-

Members of the board	Title	Age	Since
Yue Min Chung BRD	Director/Board Member	59	22-07-09
Shu Ling Chiang BRD	Director/Board Member	68	-
Eugene Jiang CHM	Chairman	38	15-06-30
Tsang Ming Jiang BRD	Director/Board Member	63	17-11-22
Norimi Sakamoto BRD	Director/Board Member	53	17-11-22
Yen-Hsin Chou BRD	Director/Board Member	43	17-11-22
Tsung-Shann Jiang CTO	Chief Tech/Sci/R&D Officer	70	-
Chang-Jen Jiang BRD	Director/Board Member	68	-
Yoshinobu Odaira BRD	Director/Board Member	76	-
Hsin-Hui Miao BRD	Director/Board Member	57	22-06-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,560,421	7,711,924 ( 73.03 %)	0	73.03 %

Name	Equities	%	Valuation
Eugene Jiang 7.946 %	839,111	7.946 %	1 M $
Shuling Jiang 7.425 %	784,105	7.425 %	1 M $
The Lind Partners LLC 2.281 %	240,834	2.281 %	315 493 $
Renaissance Technologies LLC 0.3418 %	36,100	0.3418 %	47 291 $
Vanguard Group, Inc. (Subfiler) 0.2580 %	27,247	0.2580 %	35 694 $
Citadel Securities GP LLC 0.2572 %	27,158	0.2572 %	35 577 $
Geode Capital Management LLC 0.1845 %	19,480	0.1845 %	25 519 $
Yoshinobu Odaira 0.1550 %	16,371	0.1550 %	21 446 $
Tsang Ming Jiang 0.005748 %	607	0.005748 %	795 $
Tower Research Capital LLC 0.005473 %	578	0.005473 %	757 $

ABVC BioPharma, Inc.

44370 Old Warm Springs Boulevard

94538, Fremont

http://www.abvcpharma.com

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.42

Average target price

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ABVC BIOPHARMA, INC.	+22.41%	14.96M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.44%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.82%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs